anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The purpose of this study was to screen Copy Number Variations (CNVs) in 35 unsolved Inherited Retinal Dystrophy (IRD) families. Initially, next generation sequencing, including a specific Hereditary Eye Disease Enrichment Panel or Whole exome sequencing, was employed to screen (likely) pathogenic Single-nucleotide Variants (SNVs) and small Insertions and Deletions (indels) for these cases. All available SNVs and indels were further validated and co-segregation analyses were performed in available family members by Sanger sequencing. If not, after excluding deep intronic variants, Multiplex ligation-dependent probe amplification (MLPA), quantitative fluorescence PCR (QF-PCR) and Sanger sequencing were employed to screen CNVs. We determined that 18 probands who had heterozygous SNVs/indels or whose parents were not consanguineous but had homozygous SNVs/indels in autosomal recessive IRDs genes had CNVs in another allele of these genes, 11 families had disease-causing hemizygous CNVs in X-linked IRD genes, 6 families had (likely) pathogenic heterozygous CNVs in PRPF31 gene. Of 35 families, 33 different CNVs in 16 IRD-associated genes were detected, with PRPF31, EYS and USH2A the most common disease-causing gene in CNVs. Twenty-six and 7 of them were deletion and duplication CNVs, respectively. Among them, 14 CNVs were first reported in this study. Our research indicates that CNVs contribute a lot to IRDs, and screening of CNVs substantially increases the diagnostic rate of IRD. Our results emphasize that MLPA and QF-PCR are ideal methods to validate CNVs, and the novel CNVs reported herein expand the mutational spectrums of IRDs.
Patients receive carboplatin IV over 1 hour and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients may undergo treatment with paclitaxel and may also receive 6 more courses of neoadjuvant chemotherapy. Patients may then undergo surgery. After surgery, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Patients receive docetaxel as in Arm 1A and oral capecitabine (cape) twice daily on days 1-14 every 3 weeks for up to 4 cycles. Patients then receive AC as in Arm 1A. Patients then undergo surgery as in Arm 1A.
Clonidine is an alpha2-adrenergic agonist with sedative, analgesic and hemodynamic properties. It inhibits transmission of nociceptive stimuli in the dorsal horn of the spinal cord, acting on the inhibitory descending pathways.
For condition 1a, 3600 pulses of 10-Hz TMS or 3600 pulses of cTBS. 10 Hz rTMS (110% RMT stimulation intensity; 10 Hz frequency; 5 s on and 26 s off; 3600 pulses per session; total duration of 40 min). cTBS (80% RMT, (3 pulses at 50 Hz with a repeated frequency of 5 Hz, 200 ms intervals, containing 1800 pulses, 60 second break, 1800 pulses; total duration of 5 minutes).
FIELD: medicine. ^ SUBSTANCE: invention refers to a soft capsule containing a compound, causing irritation in oral cavity, particularly, (2R)-2-propyloctane acid or its salt. Said compounds are suitable as an agent to prevent, treat and/or delay of progression of symptoms of various neurodegenerative diseases. The capsule exhibits durability 150 to 400 H when crack-tested, decay time 3 to 10 minutes when disintegration tested. ^ EFFECT: soft capsule under the invention is chewing-resistant, it can be ingested safely without sensation of burning, hotness, pain in oral cavity; the capsule ensures long storage without solubility delay. ^ 34 cl, 24 tbl, 8 ex
This article primarily introduces a new treatment for liver fibrosis/cirrhosis. We developed a hepatic patch by combining decellularized liver matrix (DLM) with the hepatocyte growth factor (HGF)/heparin-complex and evaluated its restorative efficacy. In vitro prophylactic results, the HGF/heparin-DLM patches effectively mitigated CCl4-induced hepatocyte toxicity and restored the cytotoxicity levels to the baseline levels by day 5. Furthermore, these patches restored albumin synthesis of injured hepatocytes to more than 70% of the normal levels within 5 days. In vitro therapeutic results, the urea synthesis of the injured hepatocytes reached 91% of the normal levels after 10 days of culture, indicating successful restoration of hepatic function by the HGF/heparin-DLM patches in both prophylactic and therapeutic models. In vivo results, HGF/heparin-DLM patches attached to the liver and gut exhibited a significant decrease in collagen content (4.44 times and 2.77 times, respectively) and an increase in glycogen content (1.19 times and 1.12 times, respectively) compared to the fibrosis group after 1 week, separately. In summary, liver function was restored and inflammation was inhibited through the combined effects of DLM and the HGF/heparin-complex in fibrotic liver. The newly designed hepatic patch holds promise for both in vitro and in vivo regeneration therapy and preventive health care for liver tissue engineering.
Protocol is the same for extended or flexed knee. The testing apparatus was set up as described in the constructor owner's manual and subjects were positioned in the supine lying position. The After a 5 min rest period, the participant's ankle is passively stretched through slow loading cycles from 15° of ankle flexion to 35° of ankle extension. Oral instruction is given to the participants to stay relaxed and avoid any muscle contraction and movement of the leg throughout the passive stretching. To familiarize, participant have 3 repetitions of passive ankle flexion-extension at 5°.s-1, and after 2min rest, data are collected from one repetitions at 5°.s-1 in passive mode. The measurements are also performed at an angular rate of 90°.s-1, according to the same protocol. Data for maximal voluntary isokinetic contraction are collected from 3 maximal repetitions at 60°.s-1 in concentric mode and participant are encouraged by constant verbal stimulation.
OBJECTIVE: To study the characteristics of postmortem ethanol production and its relation with alcohol congeners in postmortem rat liver and muscle tissues.
METHOD: Postmortem liver and muscle tissues in Sprague-Dawley rats, from postmortem time interval (PMI) day 0-20, were analyzed via headspace gas chromatograph flame ionization detection to observe production of postmortem ethanol and 5 selected alcohol congeners.
RESULT: 1. Putrid ethanol production increased gradually to a peak and then decreased with the prolongation of PMI; 2. Acetaldehyde, 1-propanol, and 3-methyl-butyraldehyde were produced along with postmortem ethanol; 1-butanol was only detected from day 11-20; 3. The concentrations of acetaldehyde, 1-propanol and 3-methyl-butyraldehyde was related with ethanol production. Fifteen mathematical models were constructed for putrid ethanol production based on acetaldehyde, 1-propanol, and 3-methyl-butyraldehyde.
CONCLUSION: A peak in postmortem ethanol production was identified. The production trends of acetaldehyde, 1-propanol, and 3-methyl-butyraldehyde in the liver, and of 1-propanol in muscle, were consistent with those of ethanol, and could potentially to be used as biomarkers of postmortem ethanol production. Further human samples and data analysis are needed to verify this.
A method of treating a clinical condition in a subject with a psychoactive substance such as a cannabinoid (e.g. CBD or THC) or a psychedelic drug. The user is provided with a therapeutic product containing the psychoactive substance. For example, the therapeutic product may be one or more vials of CBD oil. The user interacts with an online program (e.g. via a smartphone app) that instructs the user about their dosing of the therapeutic product. Depending on the progress of their symptoms, the online program may instruct the user to increase their dose, reduce their dose, or keep the same dose. The online program continues for a set duration of time (e.g. nine days). As a result of completing the program, the user will have a more personalized dosing of the therapeutic product.
<P>PROBLEM TO BE SOLVED: To provide a method for producing a pharmaceutical for eliciting cytotoxic T cell response to tumor cells forming a Type III mutant EGF(epidermal growth factor) receptor.  <P>SOLUTION: Cell lines which overexpress a Type III mutant EGF receptor are provided. Methods for producing these cell lines are also provided. Further, antibodies raised against peptides expressed by these cell lines are provided. Vaccines comprising peptides from a fusion junction present in a mutant human EGF receptor and methods for using these vaccines in the inhibition of tumor formation and enhancement of tumor regression are also provided, respectively. Furthermore, antisense oligonucleotides targeted to a mutant EGF receptor which decreases expression of the mutant EGF receptor are provided.  <P>COPYRIGHT: (C)2008,JPO&INPIT
NEW MATERIAL:A physiologically active substance TAN-883-B having the following physicochemical properties or a salt thereof. The shape: white powder; molecular formula: C20H40N2O6, etc. USE:An angiogenesis-promoting drug. Useful for recovering of wounds accompanied with large surgical operations such as burns, wounds, fractures and organic transplantations, for improving sewed opening disorders and recovery delayed diseases and for the diseases requiring the rapid hyperplasia of angiogenesis, such as ischemic heart diseases, e.g. cardiac infarct and cerebral hemorrhage accompanying arterial sclerosis, and digestive tract ulcer, etc. PREPARATION:A microorganism belonging to the Lysobacer genus, such as Lysobacer gummosus B62-21 strain (FERM BP-2568) is cultured preferably with aerial stirring at 17-28 deg.C at a pH of 5.5-7.0 for 24-144 hours.
The pantothenic acid salts of streptomycin, dihydrostreptomycin, neomycin and viomycin are produced by reacting a salt of the basic antibiotic with pantothenic acid or a functional derivative of this acid which in the living organism can be transformed into pantothenic acid or which can liberate this acid, e.g. pantothenal, pantothenic acid lactone, pantothenol, pantothenic acid amides and esters of pantothenic acid in which the hydroxyl group of pantothenic acid is esterified with an acid such as phosphoric acid, acetic acid or phthalic acid, or the carboxyl group of pantothenic acid is esterified with an alcohol such as a monohydric alcohol containing 1 to 6 carbon atoms or inositol.  It is preferred to react a salt of the antibiotic, e.g. sulphate, with an alkali metal or alkaline earth metal salt of pantothenic acid.  Examples describe the preparation of (a) streptomycin pantothenate, (b) dihydrostreptomycin pantothenate, (c) mixed salts of (a) and (b), (d) neomycin pantothenate and (e) viomycin pantothenate.  The salts may be incorporated in medicines (see Group VI).  Specification 687,500 is referred to.ALSO:Medicines comprise a therapeutically active product wherein streptomycin, dihydro-streptomycin neomycin, niomycin or a salt thereof is reacted to form a chemical compound (see Group IV(b)) or is worked up to form a medicinal mixture, with pantothenic acid or a functional derivative of this acid which in the living organism can be transformed into pantothenic acid or which can liberate this acid e.g. pantothenal, pantothenic acid lactone, pantothenol, pantothenic acid amides and esters of pantothenic acid in which the hydroxyl group of pantothenic acid is esterified with an acid such as phosphoric acetic or phthalic, or the carboxyl group of the pantothenic acid is esterified with an alcohol such as a monohydric alcohol containing 1 to 6 carbon atoms or inisitol.  The presence of the pantothenic acid compound eliminates the undesirable secondary effects produced by the administration of the said antibiotics.  The preparations may be administered in the form of solutions, powders and ointments and other active ingredients e.g. penicillin, procaine penicillin or oxycaine penicillin may be present.  Specification 687,500 [Group IV(b)] is referred to.
Prior epidemiological research has indicated a possible association between atrial fibrillation (AF) and frailty status. Our study used Mendelian randomization to estimate its causality. The genome-wide association studies for AF were utilized as the exposure for individuals included in the UK Biobank (n = 463,010) and publicly available summary statistics data sets of genome-wide association studies meta-analyses for frailty index in individuals of European descent (n = 175,226) was used as the outcome. The inverse variance weighting method was utilized to evaluate causality. To further confirm the reliability of the results, sensitivity analyses were conducted. The inverse variance weighting analysis indicated that the presence of AF was found to be statistically linked to an increased risk of frailty (odds ratio = 3.017, CI: 1.106-8.232, P = .031). MR-Egger intercept test indicated no pleiotropy (Egger intercept = .002, P = .808). The leave-one-out method indicated that the individual SNPs did not have an impact on the robustness of the findings. The research implies a causal relationship between AF and frailty. Early detection and timely intervention of AF can control the occurrence of frailty.
A growing body of data indicates that patients with posttraumatic stress disorder (PTSD) have regionally selective alterations in brain metabolism and processing of information. For example, neuroimaging studies reveal increased blood flow and glucose utilization in right frontal, limbic and paralimibic brain structures in patients with PTSD, particularly when they are recalling the traumatic event associated with their symptoms. These alterations in regional brain activity are thought to be related, in part, to the distressing emotional symptoms associated with traumatic memories. Autonomic Nervous System (ANS) dysregulation is common in PTSD, with sympathetic hyper-reactivity and relative lack of parasympathetic modulation. In addition, abnormalities in hormone levels such as thyroid hormones and the hypothalmic-pituitary-adrenal axis have been demonstrated. Repetitive transcranial magnetic stimulation may provide a non-invasive technique for normalizing the alterations in regional brain metabolism, possibly leading to improvements in PTSD symptoms and concomitant improvement in ANS and hormonal balance. In particular, preliminary clinical data indicate that low frequency (i.e., approximately 0.9-1 Hz) rTMS stimulation leads to a decrease in regional cerebral blood flow. The purpose of the present study is to determine, using a placebo-controlled, parallel design, whether right frontal rTMS stimulation in patients with posttraumatic stress disorder leads to symptomatic improvement, reductions in hemispheric regional blood flow, and improvements in ANS regulation. The study hypothesis is that 1 Hz right frontal rTMS stimulation will be superior to sham stimulation in reducing PTSD symptoms and physiology including improving abnormalities in regional cerebral blood flow, vagal tone, and circulating hormone levels.
Despite the importance of adoption and maintenance of habitual moderate to vigorous-intensity physical activity (MVPA) for health benefits and long-term weight management, current comprehensive lifestyle interventions place little emphasis on physical activity behavior change strategies and have only modest impact on MVPA. Acceptance and Commitment Therapy (ACT), a well validated, newer generation behavioral approach uses values of clarification and commitment strategies, along with acceptance-based skills training, to effect health behavior change that is consistent with personally identified values. ACT presents a theoretically consistent and potentially powerful intervention framework from which to target values-based autonomous motivation and increase MVPA. The overall aim of this study is to test the feasibility, acceptability, and preliminary efficacy of an ACT-based workshop intervention for increasing bout-related MVPA for overweight and obese, insufficiently active adults using a single-arm design. We will recruit 48 overweight/obese, insufficiently active adults across multiple cohorts and provide them with a 4-hour, ACT-based workshop followed by weekly emails and monthly phone calls for 3 months. The primary goal of the workshop is to use values clarification and acceptance-based skills training to increase values-based autonomous motivation and bout-related MVPA. Participants will self-monitor and report on progress via weekly emails and monthly phone calls. Assessments will be at baseline, 3, and 6 months. The goal of this study is threefold: 1) to determine the feasibility and acceptability of the ACT workshop intervention by assessing the completion of the intervention at all time points and via questionnaires; 2) to show changes in autonomous motivation and values-consistent behavior at the end of the intervention; and 3) to show changes in physical activity, by use of an objectively measured physical activity devices, where participants are engaging in at least 200 minutes of MVPA at 3 and 6-months)

This study will be conducted at the Miriam Hospital Weight Control and Diabetes Research Center by Drs. Jason Lillis and Dale Bond.
Patients of the controlled group are informed of their allocation results along with a reminder of the next clinic visit. On the second visit at the 1st month, measurements of clinical symptoms and inflammation status are conducted. No mulberry juice is given to patients further on. All patients are evaluated again with the same assessment tools, as well as the immunology markers in their sera during the third visit.
Nanostructures are made that include at least one species of assembly unit in which at least one joining element is a pilin protein or binding-derivative or binding-fragment thereof. The pilin-containing assembly units may have two pilin-derived joining elements, and may contain structural elements, functional elements or both. The nanostructure is suitably prepared using a staged assembly method, in which a nanostructure intermediate having at least one unbound joining element is contacted with an assembly unit having a plurality of different joining elements. None of the joining elements of the assembly unit can interact with itself or with another joining element of the same assembly unit. However, one of the joining elements can interact with the unbound joining element of the nanostructure intermediate, so that the assembly unit is non-covalently bound to the nanostructure intermediate. Unbound assembly units are removed and the cycles are repeated for a sufficient number of cycles to form a nanostructure. The complementary joining elements in at least one cycle include a pilin protein or a binding derivative or binding fragment thereof.
Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic disease. Every 3 in 4 adults have diabetes in low and middle income countries. Diabetes costs about 966 billion USD dollars in total health expenditure. This is a huge economic burden for low and middle income countries, where people have to pay out of their pocket for medical expense. Type2 Diabetes is responsible for various serious life threatening complications like cardiovascular death, retinopathy, nephropathy, stroke etc.

Along with diet and exercise, lifelong pharmacotherapy is needed. But cost of drug is increasing day by day, especially newer agents are very much expensive. The aim of this study is to compare the cost and effectiveness of Metformin plus sulfonylureas with Metformin plus DPP4 inhibitors in management of type 2 diabetic patient. This research will be conducted in Pharmacology department of Bangabandhu Sheikh Mujib Medical University (BSMMU), outpatient department of BIRDEM General Hospital, and Siddhirganj diabetic center, Narayanganj from the day of approval by IRB to July, 2024. It will be multi centered, retrospective, observational, cost-effectiveness study. It will involve type 2 diabetic patients who have diagnosed for 2 years and taking either any of sulfonylurease or DPP4 inhibitors along with Metformin. 206 patients will be enrolled, 103 in each group. One group will who are taking sulfonylureas with Metformin and another group will who are taking DPP4 inhibitors with Metformin. Primary outcome will be glycemic control which will be measured by HbA1c % and secondary outcome will be cardiovascular events like hypertension, angina, myocardial ischemia for which ECG and patients medical record will be analyzed, nephropathy will be classified by eGFR, insulin therapy and any hospitalization needed or not. Data will be collected about various socio-demographic variables such as age, sex, education, family history of diabetes, other co morbidities. Hypertension with diabetes will be considered in equal percentage in both groups. Total direct medical cost like drug price, hospitalization and cost of adverse drug reaction will be measured which will be actual medical cost of individual patient. Then cost-effectiveness analysis will be done by ICER. Descriptive statistics will be used for demographic variables. Means \& standard deviation for ii continuous variables and number \& percentage for categorical variables will be used. T test can be used to compare cost in two groups. Chi-square test may be used to compare clinical outcome. Price of drug will be obtained from BDNF 5th edition for particular brand of above mentioned drug in every individual patient. This study will revealed whether there is significant difference in healthcare costs and clinical outcome between the above mentioned two groups. This retrospective study will provide valuable insight about cost effectiveness of sulfonylureas and DPP4 inhibitors for the management of T2DM. Healthcare providers even policymakers can be benefitted to take informed decision in patient care and formulary choices.
Anaplastic large cell lymphoma (ALCL) is a rare non-Hodgkin's lymphoma, around 30% patients would get relapse. Vinorelbine(Navelbine) is a third-line treatment option for Hodgkin's disease(HD) after transplantation failed, while both HD and ALCL express CD30. When ALCL recurred, vinblastine monotherapy was used and the 5-year EFS up to 30%, 5-year OS up to 60%. In China vinblastine is unavailable. Vinorelbine is very similar to vinblastine in molecular formula, and is available in China. From November 2016 to March 2017, two patients with recurrent ALCL were recruited in the Department of Hematology and Oncology, Shanghai Children's Medical Center. They received vinorelbine monotherapy and achieved clinical remission (PET CR) at 8 weeks. One patient with bone marrow recurrence showed negative ALK / NPM by PCR . Based on this, the investigators will expand the sample to further investigate the therapeutic efficiency and safety of vinorelbine in children and adolescents with ALCL.